Title |
Molecular mechanisms of statin intolerance
|
---|---|
Published in |
Archives of Medical Science, May 2016
|
DOI | 10.5114/aoms.2016.59938 |
Pubmed ID | |
Authors |
Anna Gluba-Brzozka, Beata Franczyk, Peter P. Toth, Jacek Rysz, Maciej Banach |
Abstract |
Statins reduce cardiovascular morbidity and mortality in primary and secondary prevention. Despite their efficacy, many persons are unable to tolerate statins due to adverse events such as hepatotoxicity and myalgia/myopathy. In the case of most patients, it seems that mild-to-moderate abnormalities in liver and muscle enzymes are not serious adverse effects and do not outweigh the benefits of coronary heart disease risk reduction. The risk for mortality or permanent organ damage ascribed to statin use is very small and limited to cases of myopathy and rhabdomyolysis. Statin-induced muscle-related adverse events comprise a highly heterogeneous clinical disorder with numerous, complex etiologies and a variety of genetic backgrounds. Every patient who presents with statin-related side effects cannot undergo the type of exhaustive molecular characterization that would include all of these mechanisms. Frequently the only solution is to either discontinue statin therapy/reduce the dose or attempt intermittent dosing strategies at a low dose. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Poland | 2 | 50% |
Argentina | 1 | 25% |
Unknown | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 50% |
Members of the public | 1 | 25% |
Scientists | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 99 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 20 | 20% |
Student > Bachelor | 16 | 16% |
Researcher | 12 | 12% |
Student > Ph. D. Student | 7 | 7% |
Student > Doctoral Student | 6 | 6% |
Other | 21 | 21% |
Unknown | 17 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 34 | 34% |
Biochemistry, Genetics and Molecular Biology | 11 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 10% |
Nursing and Health Professions | 9 | 9% |
Agricultural and Biological Sciences | 6 | 6% |
Other | 7 | 7% |
Unknown | 22 | 22% |